HANALL BIOPHARMA, a research and development (R&D)-focused subsidiary of Daewoong Pharmaceutical, said on the 29th that, on a consolidation basis, its sales for the third quarter of this year were 40.8 billion won, up 10.8% from the same period a year earlier, and operating profit was 350 million won, down 18.8% from a year earlier. Net profit was 300 million won, up 34.7%.
Sales of pharmaceuticals in the third quarter of this year were 35.5 billion won, up 11.5% from the same period a year earlier.
According to the company, the probiotic drug "Biotop" ranked No. 1 in the UBIST market for prescriptions of microbiological antidiarrheals in August, and sales of the prostate cancer and precocious puberty treatment "Eligard" reached 10 billion won. The hair loss treatment "HAIRGRO" recorded its highest monthly sales in September with sales of 2.5 million tablets and maintained the No. 1 position in the prescription dispensing market for finasteride 1 mg generics.
The company said there was meaningful progress in the research and development institutional sector as well. The autoimmune disease treatment candidate "Batoclimab (HL161BKN)" presented the potential to serve as a fundamental therapy for patients who did not respond to existing treatments through six-month maintenance-effect data after discontinuing Graves' disease (GD) treatment in phase 2 in September.
Clinical results showed that for six months after discontinuing Batoclimab, about 80% of patients maintained normal thyroid hormone levels, and half of them remained stable even without antithyroid drugs. In the fourth quarter, results from a phase 3 trial in thyroid eye disease (TED) are scheduled to be secured.
Research and development of "Imerofrubat (HL161ANS)," under development as a next-generation FcRn therapy, is proceeding as planned. Imerofrubat is being developed for a total of six autoimmune diseases based on Batoclimab's clinical data: myasthenia gravis (MG), Graves' disease (GD), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren's syndrome (SjD), and cutaneous lupus erythematosus (CLE).
The dry eye disease treatment "Tanfanercept" is undergoing clinical trials with the goal of announcing topline data in 2026. The Parkinson's disease treatment "HL192" also aims to enter the next clinical stage in 2026. The company said it is continuing research on an mRNA lipid nanoparticle (LNP)-based antiaging therapy introduced last year and strengthening its immunology-based research and development capabilities.
Jeong Seung-won, CEO of HANALL BIOPHARMA, said, "The third quarter was a meaningful period in which progress in innovative new drug trials combined with solid pharmaceutical sales allowed us to strengthen our fundamentals," adding, "We will do our best to generate sustainable results and continue efforts to maximize the value of the pipeline currently under development."